Abivax (AAVXF) Long-Term Debt Repayments (2024 - 2025)
Abivax (AAVXF) posted Long-Term Debt Repayments of -$62.7 billion for Q4 2025, down 434053.23% on a QoQ basis from -$14.5 million in Q3 2025, and down 571.59% year-over-year from $13.3 billion in Q4 2024.
Powered by 
Analysis
Abivax (AAVXF) Long-Term Debt Repayments (2024 - 2025) Analysis & Trends
Abivax has reported Long-Term Debt Repayments for 2 years, with the latest figure at -$62.7 billion in Q4 2025.
- On a quarterly basis, Long-Term Debt Repayments fell 571.59% year-over-year to -$62.7 billion in Q4 2025; TTM through Mar 2026 was -$62.8 billion, a 571.11% decrease from a year earlier, with the FY2025 full-year figure at -$62.8 billion, down 571.27% from the prior year.
- Long-Term Debt Repayments was -$62.7 billion for Q4 2025 at Abivax, down from -$14.5 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $1.7 million in Q2 2025, with the low at -$62.7 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | - |
| 10 | Abivax | 10.92 Bn | 10.92 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -62.75 Bn |
| Sep 30, 2025 | -14.45 Mn |
| Jun 30, 2025 | 1.72 Mn |
| Mar 31, 2025 | -3.90 Mn |
| Dec 31, 2024 | -9.34 Bn |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | -2.36 Mn |
| Mar 31, 2024 | -2.38 Mn |